Secondary analysis of SONIA in 260 patients with HR+HER2- advanced breast cancer on aromatase inhibitors: no group-level cognitive decline over 9 months with or without CDK4/6 inhibitors; 15.7% vs 14.3% showed meaningful individual decline.
Secondary analysisn = 260
Luijendijk et al. Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancer